Skip to content

Released Nov 12, 2026, before the open

10-Q filed Nov 12, 2026, 43 days after period end · 0001193125-26-458388

Q3 2026 · 10-Q
Revenue$2.11M— vs Q3 2025+1,328.4% vs Q2 2026
Net Income-$44.49MN/M vs Q3 2025N/M vs Q2 2026
EPS Diluted-$0.36N/M vs Q3 2025N/M vs Q2 2026
Operating Income-$54,736,000N/M
Operating Cash Flowderived-$41,079,000N/M
Free Cash Flowderived-$41,690,000N/M
Margins · derived
Operating margin-2589.2%
Net margin-2104.6%

What the release said

On November 12, 2026, Parabilis Medicines, Inc. (the “Company”) announced its financial results and business highlights for the quarter ended September 30, 2026.

Parabilis Medicines reported a net loss of $44.5 million for the quarter ended September 30, 2026, compared to $33.5 million for the comparable prior-year period.2

Revenue was $2.1 million from collaboration agreements, research and development expenses were $45.6 million, and general and administrative expenses were $11.3 million for the quarter.345

Cash, cash equivalents and marketable securities were $1.1 billion as of September 30, 2026, which the company expects to fund operations into 2030.67

The company reached alignment with the U.S. Food and Drug Administration on a global Phase 3 trial design and plans to initiate the PEDESTAL registrational trial in the first half of 2027.89

Net loss
$44.5 million Quarter ended September 30, 2026, compared to $33.5 million for the comparable prior-year period2
Revenue
$2.1 million Quarter ended September 30, 2026, from collaboration agreements, compared to no revenue in the comparable prior-year period3
Research and development expenses
$45.6 million Quarter ended September 30, 2026, compared to $28.2 million for the comparable prior-year period4
General and administrative expenses
$11.3 million Quarter ended September 30, 2026, compared to $6.6 million for the comparable prior-year period5
Cash, cash equivalents and marketable securities
$1.1 billion As of September 30, 2026, compared to $27.7 million as of December 31, 20257
Thaler Agent · checked against the filing
Open the reading ›
The release

Same quarter

MetricQ3 2026Q3 2025
Revenue$2.11M$0.00
Net Income-$44.49M-$33.48M
EPS Diluted-$0.36-$21.66

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Parabilis Medicines, Inc. · CIK 1657677 · Engraved from SEC EDGAR